NCT04394351 - Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE) | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

June 2, 2022

Study Completion Date

May 14, 2024

Conditions

Eosinophilic Esophagitis (EoE)

Interventions

DRUG

Dupilumab

Single-use, prefilled syringe

DRUG

Matching Placebo

Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance

Trial Locations (27)

10029

Regeneron Study Site, New York

10032

Regeneron Study Site, New York

10065

Regeneron Study Site, New York

19104

Regeneron Study Site, Philadelphia

27599

Regeneron Study Site, Chapel Hill

30322

Regeneron Study Site, Atlanta

30342

Regeneron Study Site, Atlanta

33701

Regeneron Study Site, St. Petersburg

44106

Regeneron Study Site, Cleveland

45229

Regeneron Study Site, Cincinnati

46202

Regeneron Study Site, Indianapolis

52242

Regeneron Study Site, Iowa City

53226

Regeneron Study Site, Milwaukee

60611

Regeneron Study Site, Chicago

68510

Regeneron Study Site, Lincoln

72202

Regeneron Study Site, Little Rock

75207

Regeneron Study Site, Dallas

76104

Regeneron Study Site, Fort Worth

77030

Regeneron Study Site, Houston

80045

Regeneron Study Site, Aurora

85016

Regeneron Study Site, Phoenix

90027

Regeneron Study Site, Los Angeles

94143

Regeneron Study Site, San Francisco

02111

Regeneron Study Site, Boston

02114

Regeneron Study Site, Boston

02115

Regeneron Study Site, Boston

N6A 5W9

Regeneron Study Site, London